VIDEO: New Skyrizi, Rinvoq data will help 'shape our clinical practice' in IBD management
Click Here to Manage Email Alerts
In a Healio video exclusive, Remo Panaccione, MD, noted the cumulative benefit of Skyrizi and Rinvoq for the induction and maintenance treatment of patients with inflammatory bowel disease.
According to phase 3 results from the ADVANCE and MOTIVATE studies presented at the European Crohn’s and Colitis Organization, Skyrizi (risankizumab, AbbVie) induced ‘rapid response and remission’ via IV induction at 12 weeks with maintained endoscopic endpoints through 52 weeks of the FORTIFY maintenance trial.
“This is really interesting because it suggests that you have these rapid initial responders and then you have some of these delayed responders,” Panaccione, professor of medicine and director of the Inflammatory Bowel Disease Clinic at the University of Calgary, said. “But, if we look at the totality of our patient population, 90% of patients will be responding by the end of 24 weeks. This data highlights the cumulative benefit of patients starting and remaining on risankizumab.”
Rinvoq (upadacitinib, AbbVie) is a selective reversible JAK 1 inhibitor that has previously been investigated for both the treatment of moderate to severe UC as well as moderate to severe CD.
“This is exciting for the field because this is a once daily oral therapy that can be given during induction and maintenance,” Panaccione added.
Data from the U-EXCEL, U-ACHIEVE and U-ENDURE trials showed upadacitinib achieved clinical, endoscopic and histological endpoints during induction and maintenance among patients with UC. Panaccione noted its ‘rapid onset of action’ resolved IBD symptoms such as increased stool frequency, rectal bleeding, bowel urgency and fatigue.
“Lots of new data at ECCO this year relating to both risankizumab in Crohn's disease and upadacitinib in both ulcerative colitis and Crohn's disease,” he concluded. “Certainly, I think this data will help us shape our clinical practice in the near and long-term.”
References:
- AbbVie. AbbVie highlights robust gastroenterology portfolio with new analyses and data in inflammatory bowel diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO). Available at: https://news.abbvie.com/article_display.cfm?article_id=12561. Accessed: March 10, 2023.
- Feagan B, et al. Presentation OP17. Presented at: European Crohn’s and Colitis Organization; March 1-4, 2023; Copenhagen.
- Panaccione R, et al. Presentation OP16. Presented at: European Crohn’s and Colitis Organization; March 1-4, 2023; Copenhagen.
- Feagan B, et al. Presentation OP17. Presented at: European Crohn’s and Colitis Organization; March 1-4, 2023; Copenhagen.
- Panaccione R, et al. Presentation OP20. Presented at: European Crohn’s and Colitis Organization; March 1-4, 2023; Copenhagen.
- Vermeire S, et al. Presentation OP04. Presented at: European Crohn’s and Colitis Organization; March 1-4, 2023; Copenhagen.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts